A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitors
The Journal of Pathology · 2024
DOI: 10.1002/path.6358 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2024. Verfasst von Ilenia Segatto und 20 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 6, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Breast cancer (BC) is marked by significant genetic, morphological and clinical heterogeneity. To capture this heterogeneity and unravel the molecular mechanisms driving tumor progression and drug resistance, we established a comprehensive patient‐derived xenograft (PDX) biobank, focusing particularly on luminal (estrogen receptor, ER+) and young premenopausal patients, for whom PDX models are currently scarce. Across all BC subtypes, our efforts resulted in an overall success rate of 17% (26 established PDX lines out of 151 total attempts), specifically 15% in luminal, 12% in human epidermal growth factor receptor 2 positive (HER2+) and 35% in triple negative BC. These PDX mirrored morphologic and genetic features of BC from which they originated, serving as a reliable tool to investigate drug resistance and test therapeutic strategies. We focused on understanding resistance to CDK4/6 inhibitors (CDK4/6i), which are crucial in the treatment of patients with advanced luminal BC. Treating a sensitive luminal BC PDX with the CDK4/6i palbociclib revealed that, despite initial tumor shrinkage, some tumors might eventually regrow under drug treatment. RNA sequencing, followed by gene set enrichment analyses, unveiled that these PDXs have become refractory to CDK4/6i, both at biological and molecular levels, displaying significant enrichment in proliferation pathways, such as MTORC1 , E2F and MYC . Using organoids derived from these PDX (PDxO), we observed that acquisition of CDK4/6i resistance conferred cross‐resistance to endocrine therapy and that targeting MTORC1 was a successful strategy to overcome CDK4/6i resistance. Considered together, these results indicate that our PDX models may serve as robust tools to elucidate the molecular basis of BC disease progression and, by providing the possibility to simultaneously test different therapies on the same tumor, to surmount treatment resistance. While this approach is of course not feasible in the clinic, its exploitation in PDX may expedite the identification and development of more successful therapies for patients with advanced luminal BC. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- Faculty of Medicine and Psychology, Department of Clinical and Molecular Medicine, University of Rome 'Sapienza', Santo Andrea Hospital, Rome, Italy.
- San Raffaele Hospital, Milan, Italy.
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- Unit of Breast Surgery, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- Unit of Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
ORCID-Profile: Barbara Belletti
Förderung
- Ministero dell'Università e della Ricerca
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro
- Alleanza Contro il Cancro
- CRO Intramural Research Seed Grant
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Segatto, I., Mattevi, M. C., Rampioni Vinciguerra, G. L., Crestan, N., Musco, L., Favero, A., Dall'Acqua, A., Di Giustino, G., Mungo, G., D'Andrea, S., Gava, C., Ruggiero, F., Dugo, M., Gerratana, L., Puglisi, F., Massarut, S., Bomben, R., Callari, M., Perin, T., …, & Belletti, B. (2024). A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitors. The Journal of Pathology. https://doi.org/10.1002/path.6358
Vancouver
Segatto I, Mattevi MC, Rampioni Vinciguerra GL, Crestan N, Musco L, Favero A, et al. A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitors. The Journal of Pathology. 2024. doi:10.1002/path.6358
BibTeX
@article{Segatto2024,
author = {Segatto, Ilenia and Mattevi, Maria Chiara and Rampioni Vinciguerra, Gian Luca and Crestan, Nicole and Musco, Lorena and Favero, Andrea and Dall'Acqua, Alessandra and Di Giustino, Gabriele and Mungo, Giorgia and D'Andrea, Sara and Gava, Chiara and Ruggiero, Federica and Dugo, Matteo and Gerratana, Lorenzo and Puglisi, Fabio and Massarut, Samuele and Bomben, Riccardo and Callari, Maurizio and Perin, Tiziana and Baldassarre, Gustavo and Belletti, Barbara},
title = {A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitors},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6358}
}
EUVIMED